Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565798 | 0.86 | PKM (0.73) | SMN1; SMN2PKMALDH1A1KMT2ANPSR1 | |
| SCHEMBL7144945 | 0.85 | PKM (0.77) | PKMALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL31172621 | 0.85 | PKM (0.54) | PKMALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL31401229 | 0.85 | PKM (0.58) | SMN1; SMN2PKMALDH1A1NPSR1LMNA | |
| SCHEMBL8729586 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2PKMALDH1A1KMT2AMEN1 | |
| SCHEMBL28042445 | 0.85 | PKM (0.54) | PKMALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL20647826 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2PKMALDH1A1NPSR1LMNA | |
| SCHEMBL11265480 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2PKMALDH1A1NPSR1TSHR | |
| SCHEMBL997219 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2PKMALDH1A1KMT2AMEN1 | |
| SCHEMBL16999093 | 0.80 | RORC (0.45) | SMN1; SMN2LMNACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505722-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225355-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-4327224-A | ADRENERGIC BLOCKING AGENTS | STERLING DRUG INC. (US) | 1982-04-27 | — | — | US | disclosed |
| US-4124722-A | USING AN A-((ALKYLAMINO)ALKYL)-4-HYDROXY-3-(ALKYL-THIO, -SULFINYL -SULFONYL)-BENZENEMETHANOL | STERLING DRUG INC. (US) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225355-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | SMN1; SMN2 4568/4885PKM 4764/4885ALDH1A1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.